Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + ribavirin + betaine
- Development stage
- Discontinued
- Lead developer
- Roche
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
A combination therapy consisting of peginterferon alfa-2a, ribavirin, and betaine that was investigated for the treatment of chronic hepatitis C virus (HCV) infection, particularly for non-responders or relapsers to previous therapy. Peginterferon alfa-2a is a pegylated form of interferon alfa-2a that has a longer half-life allowing for once-weekly dosing. Ribavirin is an antiviral medication that enhances the efficacy of interferon therapy. Betaine was added to this standard combination as an experimental approach.
- Brand names
- PegasysCopegus
- Other names
- Betaine with PegIFN/RBVBetaine + Peginterferon alpha-2a + Ribavirin
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)BHMT (Betaine-homocysteine S-methyltransferase)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)
Beyond the preview
Go deeper on peginterferon alfa-2a + ribavirin + betaine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + ribavirin + betaine.